期刊文献+

uPA在乳腺癌组织中的表达及临床意义 被引量:2

下载PDF
导出
摘要 目的:探讨尿激酶型纤溶酶原激活物(u PA)在乳腺癌中的表达及临床意义。方法:乳腺癌手术切除标本109例,乳腺腺瘤28例,应用免疫组织化学SABC法对切除组织标本进行u PA染色,分析u PA在乳腺腺瘤、乳腺癌及在乳腺癌不同病理类型和转移分类中的表达。结果:u PA的阳性表达率在乳腺腺瘤为32.14%,乳腺癌为61.48%,两组比较差异有统计学意义(P<0.05);非浸润性癌u PA的表达率明显低于浸润性癌,浸润性导管癌u PA的表达率明显低于髓样癌,有淋巴结转移组织的乳腺癌u PA的表达率显著高于无转移组织者,差异均有统计学意义(P<0.05)。结论:u PA表达可能是乳腺癌细胞侵袭和转移机制之一。
作者 王素霞
出处 《贵阳医学院学报》 CAS 2014年第6期887-888,891,共3页 Journal of Guiyang Medical College
基金 河北省张家口市科技攻关计划项目(编号:1321136D)
  • 相关文献

参考文献14

  • 1Carriero MV,Stoppelli MP.The urokinase-type plasminogen acti-vator and the generation of inhibitors of urokinase activity and sig-naling[J].Curr Pharm Des,2011(19):1944-1961.
  • 2Sorio C,Mafficini A,Furlan F,et al.Elevated urinary levels of uro-kinase-type plasminogen activator receptor(u PAR)in pancreatic ductal adenocarcinoma identify a clinically highrisk group[J].BMC Cancer,2011(11):448.
  • 3Kotzsch M,Magdolen V,Greither T,et al.Combined mRNA expres-sion levels of members of the urokinase plasminogen activator(u PA)system correlate with diseaseassociated survival of soft-tissue sarcoma patients[J].BMC Cancer,2011(11):273.
  • 4Halamkova J,Kiss I,Pavlovsky Z,et al.Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients[J].Neoplas-ma,2011(5):377-385.
  • 5Nowicki TS,Kummer NT,Iacob C,et al.Inhibition of u PAR and u PA reduces invasion in papillary thyroid carcinoma cells[J].La-ryngoscope,2010(7):1383-1390.
  • 6Zhang W,Ling D,Tan J,et al.Expression of urokinase plasmino-gen activator and plasminogen activator inhibitor type-1 in ovari-an cancer and its clinical significance[J].Oncol Rep,2013(2):637-645.
  • 7Jiang JT,Zhang LF,Zhou B,et al.Relationships of u PA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis[J].Asian Pac J Cancer Prev,2012(7):3379-3383.
  • 8王丽,宋兰英,刘运江.乳腺癌组织uPA和PAI-1表达与临床病理因素相关性的探讨[J].中华肿瘤防治杂志,2009,16(22):1765-1769. 被引量:7
  • 9Kwaan HC,Mc Mahon B.The role of plasminogen-plasmin system in cancer[J].Cancer Treat Res,2009(148):43-66.
  • 10董波,舒晓燕.尿激酶型纤溶酶原激活物对乳腺癌转移的影响[J].中华实验外科杂志,2012,29(8):1619-1619. 被引量:2

二级参考文献83

  • 1张文敏,黄纲雄,黄爱民,高凌云,高美钦,陈碧芬.uPA和PAI-1在人脑胶质瘤的表达及其与肿瘤血管生成的关系[J].解剖学研究,2005,27(1):15-18. 被引量:2
  • 2吴桂珠,郑秀.肿瘤的浸润、转移与uPA系统的关系[J].海峡预防医学杂志,2005,11(2):25-27. 被引量:4
  • 3李梦秋,陆茵.尿激酶型纤溶酶原激活物作用系统与肿瘤转移[J].实用肿瘤学杂志,2005,19(5):387-390. 被引量:3
  • 4刘运江,刘现义,刘巍,单保恩.hMAM检测乳腺癌骨髓微转移及其意义[J].中国肿瘤临床,2006,33(10):549-551. 被引量:5
  • 5:iotta i. A. Tumor invasion and metastases role of the extracel hdar matrix: Rhoads Memorial Award lecture[J]. Cancer Res, 1986, 46(1):1-7.
  • 6Ellenrieder V, Adeler G, Gress T M, et al. Invasion and metastasis in pancreatic cancer[J]. Ann Oncol, 1999. 10(Suppl 1): 46-50.
  • 7Gandolfo G M, Conyi L, Vercillo M, et al. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma[J]. Anticancer Res, 1996, 16(4B): 2155-2161.
  • 8Liu G, Shuman M A, Cohen R L, et al. Co expression ofurokinase, urokinase receptor and Pal-1 is necessary for optimum invasivenessof cultured lung cancer cells[J]. Int J Cancer, 1995. 60(4):501-506.
  • 9Vohn M, Mattem J, Koomagi R. Relationship of urokinase and urokinase receptor in non small cell lung cancer to proliferation, angiogenesis, metastasis and patients survival[J]. Oncol Rep. 1999. 6(3):611-615.
  • 10Stephan B, Florian D, Bjqrn N, et al. A pooled analysis of bone marrow micrometastasis in breast cancer[J]. N Engl J Med, 2005, 353(8): 793-802.

共引文献13

同被引文献35

  • 1Abo E L, Hassan R, Moneer M. Outcome of HER2 posi- tive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients : long follow-up of single center randomized study[ J]. Gulf J Oncolog, 2015,1 (19) :67-75.
  • 2Need E F, Sehh L A, Trotta A P, et al. The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a luminal a to a basal-like subtype[ J]. BMC Canc- er, 2015,15(1) :791.
  • 3Corben A D, Abi-Raad R, Popa I, et al. Pathologic re- sponse and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison be- tween classifications and their practical application [ J ]. Arch Pathol Lab Med, 2013,137 (8) : 1074-1082.
  • 4HARBCCK N, SCHMITT M, KATCS R E. Clinical utility of urokinase-type plasminogen activator and plasrninogen activator inhibitor- 1 determination in primary breast cancer tissue for individualized therapy concepts (J 1. Clin Breast Cancer,2012,3(3) : 196.
  • 5JANICKC F, PRCCHTL A, THOMSSEN C. Randomized adjuvant chemotherapy trial in high risk, lymph node neg- ative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type l[J~. J Natl Cancer Inst,2011,93(12) :913.
  • 6VISVADER J E, LINDEMAN G J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions[ J]. Nat Rev Cancer,2008,8(10) :755.
  • 7DUFFY M J, MCGOWAN P M, HARBECK N, et al. uPA and PAI-1 as biomarkers in breast cancer: valida- ted for clinical use in level-of-evidence-1 studies [ J 1. Breast Cancer Research Bcr, 2014,16 (4) : 1.
  • 8BELLOCQ J P, LUPORSI E, BARRI~RE J,et al. uPA/ PAI-1, Oncotype DX, MammaPrint(?). Prognosis and predictive values for clinical utility in breast cancer man- agement~ J 1. Annales De Pathologie,2014,34 (5) :349.
  • 9AKUDUGU J, SERAFIN A, BHM L. Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases [ J 1. Journal of Cancer Research & Clinical Oncology, 2014,141(4) :627.
  • 10王丽,宋兰英,刘运江.乳腺癌组织uPA和PAI-1表达与临床病理因素相关性的探讨[J].中华肿瘤防治杂志,2009,16(22):1765-1769. 被引量:7

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部